Effect of erythropoeitin on visual function of patients with non-arteritic anterior ischemic optic neuropathy

Comparison of effect of intavitreal injection of erythropoeitin with intravenous erythropoeitin on visual function of patients with non-arteritic anterior ischemic optic neuropathy with control group

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201102275914N2

Enrollment

150

Registered

2011-03-05

Start date

2011-03-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ischemic optic neuropathy. Disorders of optic nerve, not elsewhere classified

Interventions

Intervention 1: Group3: Admitting the patient. 1st day : Slow intravenous infusion of 20000 units of erythropoeitin with controlling vital signs every 15minutes during infusion

recording visual acuity 2nd day : as above 3rd day : as above. Intervention 2: Group 2 : Intra vitreal injection of 2000 units of erythropoeitin in 0.2cc with 29 gauge needle under sterile condition i

Treatment - Drugs

Group3: Admitting the patient. 1st day : Slow intravenous infusion of 20000 units of erythropoeitin with controlling vital signs every 15minutes during infusion

recording visual acuity 2nd day : as above 3rd day : as above

Group 2 : Intra vitreal injection of 2000 units of erythropoeitin in 0.2cc with 29 gauge needle under sterile condition in operating room, 4 mm from limbus in phakic and 3 mm from limbus in aphakic or

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria : patients with non-arteritic anterior ischemic optic neuropathy with decreased vision, optic disc swelling, compatible visual field defects; normal ESR and CRP; lack of signs and sypmtoms suggesting giant cell arteritis(headache, jaw claudication); normal Na, Mg, K, liver function tests, Hgb; refered within 2 weeks after onset of decreased vision. Excluson criteria: high ESR and CRP; signs and sypmtoms suggesting giant cell arteritis; abnormal Na, Mg, K, liver function tests, Hgb; refered after 2 weeks of decreased vision; current smoking habbit

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Visual acuity. Timepoint: first and 7th day, 1st and 3rd and 6th month. Method of measurement: ?Sellen chart and convertion to logMAR.	—

Secondary

Measure	Time frame
Visual field. Timepoint: 1st and 7th day, 1st and 3rd and 6th month. Method of measurement: Humphery perimetry, SITA standard 24-2 strategy.;Retinal nerve fiber layer thickness. Timepoint: 1st day and 1st,3rd,6th ,. Method of measurement: Optical coherence tomogram(OCT).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactReza Soudi

Tehran University ofMedical Sciences

rezasoudi@yahoo.com+98 21 4441 5677

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026